Securities code: Honz Pharmaceutical Co.Ltd(300086) securities abbreviation: Honz Pharmaceutical Co.Ltd(300086) Announcement No.: 2022015 Honz Pharmaceutical Co.Ltd(300086) 2021 annual report summary
1、 Important note: the summary of this annual report comes from the full text of the annual report. In order to fully understand the company’s operating results, financial status and future development plan, investors should carefully read the full text of the annual report in the media designated by the CSRC. The audit opinion of Zhongshen Zhonghuan Certified Public Accountants (special general partner) on the company’s financial report this year is: standard unqualified opinion. Changes of accounting firm during the reporting period: the company’s accounting firm has not changed this year and is still China audit Zhonghuan accounting firm (special general partner). Tips of non-standard audit opinions □ applicable √ not applicable when the company is listed and is not profitable at present □ applicable √ not applicable to the profit distribution plan of ordinary shares or the plan of converting accumulation fund into share capital in the reporting period considered by the board of directors □ applicable √ not applicable. The company plans not to distribute cash dividends, bonus shares or convert accumulation fund into share capital. Preferred stock profit distribution plan for the reporting period adopted by the board of directors □ applicable □ not applicable II. Basic information of the company 1. Company profile
Stock abbreviation Honz Pharmaceutical Co.Ltd(300086) stock code Honz Pharmaceutical Co.Ltd(300086)
Shenzhen Stock Exchange
Contact person and contact information secretary of the board of directors securities affairs representative
Name: Lin Dexin, Lu Fangmei
Office address: No. 6, Yaogu Third Road, Yaogu Industrial Park, Haikou national high tech Industrial Development Zone
Fax: 089866812876
Tel: 089866812876
E-mail [email protected]. [email protected].
2. Introduction to main business or products during the reporting period
(I) overview of the company’s main business
During the reporting period, the company was a leading Chinese children’s health enterprise mainly engaged in the R & D, production and sales of children’s medicine, maternal and child health products, reproductive medicine, maternal and child health medical services, medical masks and other medical devices.
At the end of the reporting period, there were 16 subsidiaries included in the scope of consolidated financial statements, including 12 primary subsidiaries and 4 secondary subsidiaries.
1. Production and sales of class II medical devices such as drugs, protective and medical masks
The company has drug production bases in Hainan, Northeast China (Shenyang Kangzhi), North China (Xiangyun pharmaceutical and Hebei Kangzhi) and Guangdong, and is building a new production base in Zhongshan, Guangdong that meets EU standards. The company has a research institute and took the lead in establishing a national enterprise postdoctoral research workstation with children’s medicine as the main research direction. The company has first-class scientific research equipment and a highly educated R & D team composed of doctors and masters, and has established long-term cooperative relations with many pharmaceutical colleges and research institutions at home and abroad.
In Guangdong Zhongshan and Hainan bases, the company has production qualification, equipment and production lines for producing medical masks, respirators and hand sanitizer gels. Medical masks and personal protective masks are approved by the European Union.
At present, the company produces and operates more than 30 varieties of children’s drugs, covering western and Chinese patent drugs with the largest sales of antipyretic and analgesic series, cold series, anti microbial series, respiratory series, anti allergy series, digestion series, nerve series and nutritional supplement Series in China. In addition, the company also has anti microbial series, antipyretic and analgesic series, respiratory series, digestive series, endocrine series, gynecological series, urinary system and other adult drugs.
The medical masks, protective masks, main medical products and their uses produced and sold by the company are as follows:
Major product functions or remarks
purpose
Children’s anti allergy series levocetirizine hydrochloride granules (exclusive dosage form) and other anti allergy exclusive dosage forms
Antipyretic ibuprofen granules such as ibuprofen granules, Xiaoer antipyretic patch and Xiaoer Qingjie granules have passed the product list consistency evaluation
Children’s cold series amjin huangmin granules, children’s aminophenol huangnamin granules, Yinhu Ganmao powder cold medicine
etc.
The children digest series Montmorillonite powder, Albumin Tannate and Barm Powder, Lacidophilin Granules, gastrointestinal digestion drug Montmorillonite powder has passed the evaluation products of Yi San, Xiao Er Ling granules, Jian Er Le granules, Aluminium Phosphate Gel and other products.
Children’s respiratory series cough orange granules, carboxymethylstein granules, children’s Magan granules, small cough and phlegm
Eryanbian granule, Xiaoer Huatan Zhike granule, etc
Children’s microbial series: cefaclor granules, ribavirin granules, antiviral oral liquid and other anti infection agents
Children’s nutritional supplement is the nutritional supplement of compound zinc iron calcium granules, sodium carboxymethyl starch solution and zinc sulfate oral liquid
Column, etc
Children’s nerve series sodium valproate syrup antiepileptic drugs
Adult anti microbial series ceftazidime tazobactam sodium for injection (3:1), ceftazidime for injection for the treatment of infectious diseases, ceftazidime for injection, Cefminox Sodium for injection, itraconazole dispersible tablets, piromycin granules of zorbactam sodium for rohong disease (3:1), ribavirin granules are national class I new drugs, Exclusive products
Endocrine series Pioglitazone Hydrochloride Orally Disintegrating Tablets and other type 2 diabetes drugs
Respiratory series Ganmao Qingre Granule, Chaihuang Qingre Granule, Reyanning granule, compound cold medicine
Banlangen Granules, etc
Antipyretic and analgesic series: nimesulide dispersible tablets, nimesulide sustained release tablets, nimesulide granules, antipyretic and analgesic drugs
etc.
Antitussive and expectorant series (huqiangli loquat dew, Maxing Cough Syrup and other antitussive and expectorant drugs)
(suction)
Gynecology series zhenrongdan mixture and other blood nourishing, liver tonifying, zhenrongdan mixture is an exclusive product for kidney, Yin nourishing and spirit nourishing
Digestion series omeprazole enteric coated capsules, Shenmei Yangwei granules, tannic acid protein tablets, digestive drugs
Tannic acid protein powder, Lactobacillus granules
Urinary series Shenshitong granules are heat clearing, dampness removing and active
Blood relieves pain and relieves pain
Stone, row stone
Medical masks for daily use and disposable medical masks
Product cover protection
Medical class I medical device product antipyretic paste physical antipyretic
Daily protection of self-priming filter type anti particulate respirator
Other masks
2. Reproductive medicine and maternal and child health medical services
Since 2018, the company has indirectly held 51% equity of Yunnan Jiuzhou hospital Co., Ltd. and Kunming and Wanjia maternity hospital Co., Ltd. through acquisition, and added the business of reproductive medicine and maternal and child health medical services.
On June 18, 2021, June 18, 2021 and June 29, 2021, the company held the 16th meeting of the 5th board of directors, the 13th meeting of the 5th board of supervisors and the 2020 annual general meeting of shareholders respectively, and deliberated and adopted the proposal on the company selling 100% shares of Guangdong Kangzhi Hospital Management Co., Ltd. and indirectly transferring 51% shares of Yunnan Jiuzhou hospital Co., Ltd. and Kunming and Wanjia maternity hospital Co., Ltd.
The equity transfer and all delivery procedures have been completed on July 31, 2021. Since the completion of all delivery procedures, the company will no longer hold the equity of Kangzhi hospital company, and Kangzhi hospital company, Jiuzhou hospital and hewanjia hospital will no longer be included in the scope of the company’s consolidated statements.
3. Maternal and infant health products
Founded in 2003, Zhongshan love daily necessities Co., Ltd., a high-tech enterprise, has a high-standard production base. It is the industry benchmark of baby washing liquid. It is committed to providing healthy life and future for infants, children and mothers. It has two brands: love and Youmiao.
As the only maternal and infant health brand with the background of listed pharmaceutical enterprises in China, love adheres to the rigorous attitude and standards of pharmacy, establishes a strong scientific research matrix centered on Kangzhi pharmaceutical children’s Health Research Institute, and cooperates with high-end scientific research centers such as Guangdong Pharmaceutical University, South China University of technology and Japan to continuously innovate and develop products suitable for maternal and infant health care, including clothing washing, skin cleaning, facial care, body care Cleaning and disinfection, cleaning supplies, diapers, masks and other categories.
Love has won the “Guangdong provincial enterprise technology center”, “Guangdong famous brand”, “the most influential brand award”, “the best baby washing and Care Award”, “mother’s favorite reputation king”, “the supreme award of baby washing liquid industry”, the best baby moisturizer “,” the most popular brand among consumers “,” excellent national brand award “,” China good brand “and” excellent contribution award in the industry ” “Netizens’ favorite infant washing liquid Award” and “responsible Brand Award” and other honors provide safe, reliable, healthy and authoritative certified products and professional services for mothers and infants.
(1) R & D background:
1) It has the support of two R & D centers: Baby washing (care) Engineering Technology Research Center and baby care health technology research Co., Ltd. 2) In 2003, it took the lead in launching hormone free infant eczema cream in the industry.
3) In 2004, it took the lead in developing and Issuing the formula of baby washing liquid in the industry.
4) In 2016, the teaching base of Guangdong Pharmaceutical University was established.
5) In 2017, care was successfully recognized by Guangdong baby washing and care (care) Engineering Technology Research Center.
6) In 2019, love was successfully recognized by [Guangdong provincial technology center], and 12 products won the honorary certificate of “Guangdong high tech products”; And won the national high-tech enterprise recognition again.
By the end of the reporting period, Baoxi had 42 patents (China), including 41 patents for invention and utility model and 1 patent for design. There are 9 invention patents under application.
(2) Baby laundry industry benchmark:
1) In 2013, we held the national theme day of infant laundry safety, issued the new standard of safe laundry, and advocated safe laundry.
2) In 2017, he was invited to jointly participate in the formulation of the standard of liquid detergent for infant and child clothing materials, and jointly issued the group standard of liquid detergent for infant and child clothing materials with China consumer product quality and Safety Promotion Association and Guangdong pregnancy, infant and child products association in 2019.
(3) High standard production base:
1) One of the largest baby washing liquid production bases in China.
2) Products are exported to many countries around the world.
3) International standards and safety testing body
